

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Hsing-Wen Sung
Art Unit	
Examiner Name	
Attorney Docket Number	S & T- 125

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)}			
Arh		US-4,806,595	2-21-89	Noishiki et al.	all
Arh		US-5,037,664	8-6-91	Kyogoku et al.	all
Arh		US-5,085,629	2-4-92	Goldberg et al.	all
Arh		US-5,270,446	12-14-93	Kyogoku et al.	all
Arh		US-5,322,935	6-21-94	Smith	all
Arh		US-5,464,450	11-7-95	Buscemi et al.	all
Arh		US-5,516,781	5-14-96	Morris et al.	all
Arh		US-5,780,052	7-14-98	Khaw et al.	all
Arh		US-5,929,038	7-27-99	Chang	all
Arh		US-6,103,255	8-15-00	Levene et al.	all
Arh		US-6,162,826	12-19-00	Moon et al.	all
Arh		US-6,200,335	2-13-01	Itaki	all
Arh		US-6,206,931	3-27-01	Cook et al.	all
Arh		US-6,262,083	7-17-01	Moon et al.	all
Arh		US-6,264,992	7-24-01	Voytk-Harbin et al.	all
Arh		US-6,395,300	5-28-02	Straub et al.	all
Arh		US-6,423,682	7-23-02	Ballinger et al.	all
Arh		US-6,436,703	8-20-02	Tana et al.	col. 1-6

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>Rebecca M. Miller</i>	Date Considered	11/06/07
-----------------------	--------------------------	--------------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Hsing - Wen Sung
Art Unit	
Examiner Name	
Attorney Docket Number	S&T-125

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
arh		US- 6,451,764	9-17-02	Lee et al.	col. 1-6
arh		US- 6,475,784	11-5-02	Papkeff	col. 1-14
arh		US- 6,476,211	11-5-02	Ford et al.	col. 1-8
arh		US- 6,485,920	11-26-02	Ballinger et al.	col. 69-70
arh		US- 6,544,544	4-8-03	Hunter et al.	col. 1-86
arh		US- 6,545,042	4-8-03	Sung et al.	all
arh		US- 6,624,138	9-23-03	Sung et al.	all
arh		US- 6,608,040	8-19-03	Lin et al.	all
arh		US- 6,632,242	10-14-03	Igaki	all
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner
Signature

Heidi Hughes

Date
Considered

11/06/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor <i>Hsing-Wen Sung</i>	
				Art Unit	
				Examiner Name	
Sheet	3	of	5	Attorney Docket Number <i>S & T-125</i>	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
<i>all</i>	1.	RADER DJ, "High-density lipoproteins as an emerging therapeutic target for atherosclerosis", JAMA 2003; 290(17): 2322-2324		
<i>all</i>	2.	NISSEN SE et al., "Effect of Recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndroms", JAMA 2003; 290(17): 2292-2300		
<i>all</i>	3.	NAGHAVI M et al., "From vulnerable plaque to vulnerable patient - part I" Circulation 2003;108:1664-1672		
<i>all</i>	4.	NAGHAVI M et al., "From vulnerable plaque to vulnerable patient - part II" Circulation 2003;108:1772-1778		
<i>all</i>	5.	RODRIGUEZ AE et al., "Oral rapamycin in the treatment of diffuse proliferative in-stent restenosis in a patient with small reference vessel" J Invasiv. Cardiol 2003;15(9): 515-518		
<i>all</i>	6.	SUNG HW et al., "Feasibility study of a natural crosslinking reagent for biological tissue fixation" J Biomed Mater Res 1998; 42:560-567		
<i>all</i>	7.	HUANGL LL et al., "Biocompatibility study of a biological tissue fixed with a naturally occurring crosslinking reagent" J Biomed Mater Res 1998; 42: 568-576		
<i>all</i>	8.	SUNG HW et al., "In vitro evaluation of cytotoxicity of a naturally occurring cross-linking reagent for biological tissue fixation", J Biomater Sci Polymer Edn 1999; 10(1): 63-78		
<i>all</i>	9.	SUNG HW et al., "A naturally occurring crosslinking reagent for biological tissue fixation" in New Biomedical Materials, edited by Maris PI and Chapman D, pages 182-191 (1999), published by IOS Press.		
<i>all</i>	10.	SUNG HW et al., "Crosslinking characteristics and mechanical properties of a bovine pericardium fixed with a naturally occurring crosslinking agent" J Biomed Mater Res 1999; 47: 116-126		

Examiner Signature <i>Isidore Hughes</i>	Date Considered <i>11/06/2007</i>
---	--------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

5

Complete If Known

Application Number

Filing Date

First Named Inventor

Art Unit

Examiner Name

Attorney Docket Number

Hsing-Wen Sung

S&T-125

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
are	11	SUNG HW et al., "Mechanical properties of a porcine aortic valve fixed with a naturally occurring crosslinking agent" <i>Biomaterials</i> 1999; 20: 1759-1772	
are	12	SUNG HW et al., "In vitro surface characterization of a biological patch fixed with a naturally occurring crosslinking agent" <i>Biomaterials</i> 2000; 21: 1353-1362	
are	13	TSAI CC et al., "In vitro evaluation of the genotoxicity of a naturally occurring crosslinking agent (genipin) for biologic tissue fixation" <i>J Biomed Mater Res</i> 2000; 52: 58-65	
are	14	SUNG HW et al., "Fixation of biological tissues with a naturally occurring crosslinking agent: Fixation rate and effects of pH, temperature, and initial fixative concentration" <i>J Biomed Mater Res</i> 2000; 52: 77-87	
are	15	SUNG HW et al., "Extraction of a naturally occurring crosslinking agent (genipin) from Gardenia fruits and its applications in biological tissue fixation" <i>Biomaterials and Drug Delivery toward New Millennium</i> , edited by Park KD et al., pages 623-632 (2000), published by Han Rin Won Publishing Co.	
are	16	TSAI CC et al., "Effects of heparin immobilization on the surface characteristics of a biological tissue fixed with a naturally occurring crosslinking agent" <i>Biomaterials</i> 2001; 22: 523-533	
are	17	SUNG HW et al., "Stability of a biological tissue fixed with a naturally occurring crosslinking agent (genipin)" <i>J Biomed Mater Res</i> 2001; 55: 538-546	
are	18	CHANG Y et al., "Reconstruction of the right ventricular outflow tract with a bovine jugular vein graft fixed with a naturally occurring crosslinking agent (genipin) in a canine model" <i>J Thorac Cardiovas Surg</i> 2001; 122: 1208-1218	

Examiner
SignatureDate
Considered

11/06/2007

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature	<i>Leticia Hughes</i>	Date Considered	11/06/2007
-----------------------	-----------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.